General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Items 601–612 of 612
mAbs Targeting Cell Surface Antigens for Hematologic Malignancies
Cadman-Davies, L., & Silva, V. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch010
Pharmacokinetics and pharmacodynamics in brain tumor treatment
Malik, F., Shabir, H., Perveen, S., & Kanwal, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44117-2.01003-3
Malpure, S., Shirode, P., Bagga, S., Parashar, S., Lee, B., & Raina, R. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.107156
Bharti, K., Gondegaonkar, Y. Y., Deepika, D., & Kumar, V. (2026) · Toxics · doi:10.3390/toxics14100931
Kong, H., & Kim, I. (2026) · Research Square · doi:10.21203/rs.3.rs-11218379/v1
BindingDB Entry 50020068: Chemical Catalysis Guides Structural Identification for the Major
BindingDB (2024) · UC San Diego · doi:10.7270/q2r215sw
Mathematical modeling in mRNA therapeutics: toward a pathway to individualized treatment protocols
Campanile, E., Pettinà, E., & Marchetti, L. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2744578
Bending, D., Khera, E., Lam, I., Asiimwe, I. G., & Reddy, V. P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70768
Desai, D. A., & Cristofoletti, R. (2026) · Research Square · doi:10.21203/rs.3.rs-11055972/v1
Desai, D. A., & Cristofoletti, R. (2026) · Research Square · doi:10.21203/rs.3.rs-11496689/v1
Wangᵃ, Z., & Wuᵇ, X. (2026) · Authorea · doi:10.22541/authorea.15012125/v1
Euler’s and Taylor’s Expansion Method Applied on Non-linear Pharmacokinetics Model
Gombárska, D., & Beňová, M. (2014) · Advances in intelligent systems and computing · doi:10.1007/978-3-319-06593-9_32
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.